Partnerships
Leveragen partners with biotechnology, pharmaceutical, and academic organizations to enable advanced genetic engineering and antibody discovery. Our collaborations leverage proprietary genetic engineering technologies, antibody mouse platforms, and integrated discovery services, and are structured with flexible licensing and engagement models to support programs from early research through diagnostic and therapeutic development.
Genetic Engineering & Next-Generation Genetics
Leveragen provides advanced genetic engineering services for complex, high-fidelity genome modification, including direct and conditional knockouts or point mutations, single- and multi-allelic knock-ins, locus humanization, and other difficult-to-engineer designs.
Leveragen’s next-generation genetics technology enables direct, one-step generation of knockouts in the desired genetic background, eliminating multi-generation breeding and accelerating in vivo studies, including applications such as breaking immune tolerance to conserved targets.
Antibody Mouse Model Licensing
Leveragen licenses its proprietary Singularity Suite of antibody mouse platforms, developed exclusively for single-domain antibody discovery.
The Singularity Suite encompasses an unprecedented scaffold spectrum, including human VH, human Vκ, camelid VHH, shark VNAR, dog VH, cat VH, and mouse VH, enabling broad utility across therapeutic, diagnostic, and animal health applications.
Licensing is available under research, option, and commercial terms.
Integrated Antibody Discovery Services
Leveragen offers integrated antibody discovery services built around its proprietary mouse platforms.
Services span immunization, repertoire capture, phage display, NGS-guided enrichment analysis with family scanning and hit expansion, recombinant expression, and early developability assessment. Discovery workflows are modular and may be deployed as standalone services or combined with platform licensing.
Flexible Collaboration Models
Partnerships may be structured as fee-for-service engagements, antibody platform licenses, license-plus-service programs, or co-development arrangements, with flexible commercial terms including milestone-based, royalty-bearing, or milestone- and royalty-free structures. Engagements are tailored to partner strategy, development stage, and internal capabilities.
